On Monday, GSK Plc (NYSE:GSK) shares were down after the Delaware State Court ruled that more than 70,000 lawsuits could proceed over its discontinued heartburn drug, Zantac (ranitidine). The State Court’s decision contradicts the Federal Court’s Multidistrict Litigation ruling under the same legal standard, which dismissed all cases alleging five cancer types in December 2022. GSK says the litigation in Delaware remains at an early stage, and the ruling, under the Daubert standard, relates only to whether the methodology used by plaintiffs’ experts is sufficiently reliable to allow them to present their evidence at trial. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, ...